Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: Possible therapeutic implications Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Transitional Cell
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Sirolimus
  • TOR Serine-Threonine Kinases
  • Urinary Bladder Neoplasms

abstract

  • Urothelial carcinomas of the bladder express molecules of the HIF and mTOR pathways, providing a rationale for clinical trials evaluating agents targeting these pathways. Correlation between molecules within the same pathway, and not across pathways, suggests that investigating the usefulness of a specific targeted agent might benefit from pre-treatment evaluation of pathway marker expression.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1464-410X.2010.09517.x

PubMed ID

  • 20707797

Additional Document Info

start page

  • 844

end page

  • 9

volume

  • 107

number

  • 5